Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy - PubMed (original) (raw)
Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
M Kurosaki et al. Hepatology. 1997 Mar.
Abstract
In chronic hepatitis C virus (HCV) infection, genotypes other than genotype 1b of HCV (HCV-1b) and low serum HCV-RNA levels are known to be associated with favorable outcome of interferon alfa (IFN-alpha) therapy. In addition, we recently reported a close correlation between the number of mutations in amino acid sequences 2209 to 2248 of the nonstructual protein 5A gene (NS5A2209-2248) of HCV-1b and the response to IFN-alpha. In the present study, we analyzed these viral factors in relation to the efficacy to IFN-beta, another type I IFN. The pretreatment sera of 40 patients treated with IFN-beta intravenously at 6 MU daily for 42 days were studied. HCV genotypes, serum HCV-RNA levels, and the amino acid sequence of NS5A2209-2248 in HCV-1b were determined. A sustained complete response to IFN therapy occurred in none of the ten patients with the wild-type HCV-1b who had an NS5A2209-2248 sequence identical to the prototype HCV-1b and in none of the six patients with the intermediate-type HCV-1b that had 1 mutation. In contrast, complete responses occurred in the following: 4 of 6 patients with the mutant-type HCV-1b that had five to ten mutations; 6 of 13 patients with genotype 2a of HCV (HCV-2a); and 2 of 5 patients with genotype 2b of HCV (HCV-2b). Among patients with the mutant-type HCV-1b or genotype 2 of HCV (HCV-2) the rate of complete response was significantly higher (12 of 24 vs. 0 of 16 patients, P < .001) and HCV-RNA levels were significantly lower (4.5 [4.0-6.5] vs. 6 [4.5-6.5] log copies/mL, median [range]; P < .001) compared with patients with the wild- or the intermediate-type HCV-1b. Patients with the mutant-type HCV-1b or HCV-2 whose HCV-RNA levels were lower than 6 log copies/mL had a complete response rate of 75% (12 of 16 patients) in contrast to 0% (0 of 24 patients) of the others (P < .001). These results indicate that the mutant-type HCV-1b or HCV-2 are sensitive to IFN-beta as well as IFN-alpha. In conclusion, the determination of HCV genotypes, NS5A2209-2248 of HCV-1b and serum HCV-RNA levels may facilitate the selection of patients with a high likelihood of response to IFN-beta.
Comment in
- The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
Herion D, Hoofnagle JH. Herion D, et al. Hepatology. 1997 Mar;25(3):769-71. doi: 10.1002/hep.510250346. Hepatology. 1997. PMID: 9049233 No abstract available.
Similar articles
- Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
Zeuzem S, Lee JH, Roth WK. Zeuzem S, et al. Hepatology. 1997 Mar;25(3):740-4. doi: 10.1002/hep.510250341. Hepatology. 1997. PMID: 9049228 - Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Enomoto N, et al. N Engl J Med. 1996 Jan 11;334(2):77-81. doi: 10.1056/NEJM199601113340203. N Engl J Med. 1996. PMID: 8531962 - Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K. Saito T, et al. Am J Gastroenterol. 2003 Jun;98(6):1377-83. doi: 10.1111/j.1572-0241.2003.07469.x. Am J Gastroenterol. 2003. PMID: 12818284 - [Specific antibody assay for genotyping of hepatitis C virus].
Kohara M. Kohara M. Nihon Rinsho. 1994 Jul;52(7):1728-33. Nihon Rinsho. 1994. PMID: 7521411 Review. Japanese. - [Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C: method and clinical significance on interferon (IFN) therapy].
Osada T, Iwabuchi S, Takatori M, Murayama M, Iino S. Osada T, et al. Nihon Rinsho. 1994 Jul;52(7):1747-53. Nihon Rinsho. 1994. PMID: 7521414 Review. Japanese.
Cited by
- Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling.
Sugiyama R, Murayama A, Nitta S, Yamada N, Tasaka-Fujita M, Masaki T, Aly HH, Shiina M, Ryo A, Ishii K, Wakita T, Kato T. Sugiyama R, et al. Oncotarget. 2017 Dec 21;9(5):5627-5640. doi: 10.18632/oncotarget.23562. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464023 Free PMC article. - Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.
Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Sasaki R, et al. World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125. World J Hepatol. 2015. PMID: 26052401 Free PMC article. Review. - Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.
Chu PS, Ebinuma H, Nakamoto N, Sugiyama K, Usui S, Wakayama Y, Taniki N, Yamaguchi A, Shiba S, Yamagishi Y, Wakita T, Hibi T, Saito H, Kanai T. Chu PS, et al. PLoS One. 2015 May 12;10(5):e0125664. doi: 10.1371/journal.pone.0125664. eCollection 2015. PLoS One. 2015. PMID: 25965701 Free PMC article. - Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.
Antonelli G, Scagnolari C, Moschella F, Proietti E. Antonelli G, et al. Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31. doi: 10.1016/j.cytogfr.2014.12.006. Epub 2014 Dec 30. Cytokine Growth Factor Rev. 2015. PMID: 25578520 Free PMC article. Review. - Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.
El-Shamy A, Hotta H. El-Shamy A, et al. World J Gastroenterol. 2014 Jun 28;20(24):7555-69. doi: 10.3748/wjg.v20.i24.7555. World J Gastroenterol. 2014. PMID: 24976696 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials